KA
CASI

Kozak & Associates’s CASI Pharmaceuticals CASI Stock Holding History

Kozak & Associates’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$53 – 402
2024
Q2 		$53 Hold
10
– – ﹤0.01% 378
2024
Q1 		$32 Hold
10
– – ﹤0.01% 387
2023
Q4 		$54 Hold
10
– – ﹤0.01% 360
2023
Q3 		$27 Buy
+10
New +$24 ﹤0.01% 381

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Kozak & Associates's CASI Position: Q3 2024 in Review

Kozak & Associates sold out of CASI Pharmaceuticals (CASI) in Q3 2024, closing a stake of 10 shares — an estimated $53 sold.

Kozak & Associates first reported a position in CASI in Q3 2023 and held it in 4 quarters. The position peaked at $54 in Q4 2023. 20 funds tracked by Wall St. Rank hold CASI as of Q3 2024.

  • Kozak & Associates reported no remaining CASI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Kozak & Associates sold 10 CASI Pharmaceuticals shares in Q3 2024, an estimated $53.
  • Kozak & Associates first reported a position in CASI Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Kozak & Associates's CASI Pharmaceuticals position peaked at $54 in Q4 2023.
  • 20 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2024.

Based on Kozak & Associates's 13F filing for Q3 2024, filed 17 Oct 2024.